BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment

Reuters

Mar 20

BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment

** Morgan Stanley stars coverage on Celldex Therapeutics CLDX.O with "overweight" rating and PT of $46, citing the co's "pipeline potential in alternative mast cell-mediated diseases" and a "risk/reward that is skewed to the upside"

** PT represents a 130.7% upside to stock's last close

** Says co's lead skin disease drug, barzolvolimab, has shown a "potentially market-leading efficacy profile" in chronic urticaria, a condition with "significant unmet need" and limited treatment options

** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies

** Despite competition, barzolvolimab has a "unique ability to deplete mast cells", which could give it an edge in treating most cell-mediated diseases - brokerage

** CLDX fell 50.7% in the last 12 months

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520445376"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520445376\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520445376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520445376","market":"us","top_or_hot":-1,"title":"BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment</title></head><body><p>** <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> stars coverage on Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>CLDX.O</span> with \"overweight\" rating and PT of $46, citing the co's \"pipeline potential in alternative mast cell-mediated diseases\" and a \"risk/reward that is skewed to the upside\"</p><p>** PT represents a 130.7% upside to stock's last close</p><p>** Says co's lead skin disease drug, barzolvolimab, has shown a \"potentially market-leading efficacy profile\" in chronic urticaria, a condition with \"significant unmet need\" and limited treatment options</p><p>** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies</p><p>** Despite competition, barzolvolimab has a \"unique ability to deplete mast cells\", which could give it an edge in treating most cell-mediated diseases - brokerage </p><p>** CLDX fell 50.7% in the last 12 months</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-20 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment</title></head><body><p>** <a href=\"https://laohu8.com/S/MSPQL\">Morgan Stanley</a> stars coverage on Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>CLDX.O</span> with \"overweight\" rating and PT of $46, citing the co's \"pipeline potential in alternative mast cell-mediated diseases\" and a \"risk/reward that is skewed to the upside\"</p><p>** PT represents a 130.7% upside to stock's last close</p><p>** Says co's lead skin disease drug, barzolvolimab, has shown a \"potentially market-leading efficacy profile\" in chronic urticaria, a condition with \"significant unmet need\" and limited treatment options</p><p>** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies</p><p>** Despite competition, barzolvolimab has a \"unique ability to deplete mast cells\", which could give it an edge in treating most cell-mediated diseases - brokerage </p><p>** CLDX fell 50.7% in the last 12 months</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q30VB:1","article_id":"2520445376","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520445376","pubTimestamp":1742472109,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment** Morgan Stanley stars coverage on Celldex Therapeutics CLDX.O with \"overweight\" rating and PT of $46, citing the co's \"pipeline potential in alternative mast cell-mediated diseases\" and a \"risk/reward that is skewed to the upside\"** PT represents a 130.7% upside to stock's last close** Says co's lead skin disease drug, barzolvolimab, has shown a \"potentially market-leading efficacy profile\" in chronic urticaria, a condition with \"significant unmet need\" and limited treatment options** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies** Despite competition, barzolvolimab has a \"unique ability to deplete mast cells\", which could give it an edge in treating most cell-mediated diseases - brokerage ** CLDX fell 50.7% in the last 12 months  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDX":"塞德斯医疗"},"translate_title":"BUZZ-MS开始报道Celldex，看好该公司的皮肤病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment** Morgan Stanley stars coverage on Celldex Therapeutics CLDX.O with \"overweight\" rating and PT of $46, citing the co's \"pipeline potential in alternative mast cell-mediated diseases\" and a \"risk/reward that is skewed to the upside\"** PT represents a 130.7% upside to stock's last close** Says co's lead skin disease drug, barzolvolimab, has shown a \"potentially market-leading efficacy profile\" in chronic urticaria, a condition with \"significant unmet need\" and limited treatment options** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies** Despite competition, barzolvolimab has a \"unique ability to deplete mast cells\", which could give it an edge in treating most cell-mediated diseases - brokerage ** CLDX fell 50.7% in the last 12 months (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}